JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michel Carrier
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrier, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carrier, M.
Related Collections
Right arrow Coronary disease
Right arrowRelated Article

J Thorac Cardiovasc Surg 2003;126:2109
© 2003 The American Association for Thoracic Surgery

Letter to the editor

Reply to the Editor:

Michel Carrier, MDa

a Department of Surgery, Montreal Heart Institute, Research Center, Montreal, Quebec, Canada

I thank Dr Baciewicz for his comments regarding our article and thank you for the opportunity to respond to him. We chose to compare low dose of the anti-Xa inhibitor danaparoid with standard heparin in off-pump coronary artery bypass grafting because of our significant clinical experience with the former drug. Although it is not superior to standard heparin, low-dose danaparoid offers a safe alternative for patients undergoing off-pump coronary artery bypass grafting when heparin is contraindicated.

My group and I have read with interest the reports on bivalirudin, but we remain concerned by the limited clinical data available. In fact, we found only two reports of cardiac surgical patients in the literature, with one of the patients showing a large blood drainage through the chest tubes.1,2

Our current options for patients with heparin-induced thrombocytopenia are to use low-dose danaparoid and off-pump coronary artery bypass grafting or to wait for disappearance of the antiplatelet antibodies and use a standard protocol of heparin.


   References
Top
 References
 

  1. Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg. 2002;74:2177–2179
  2. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264–265

Related Article

Reply to the Editor
Martin McKneally
J. Thorac. Cardiovasc. Surg. 2003 126: 2108. [Extract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michel Carrier
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrier, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carrier, M.
Related Collections
Right arrow Coronary disease
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS